
hey, bengster, don't scare me okay.. you think about me last night??? wakau..
where am I lately? I am still here at SJ sometimes , I quit and join you guys all the time.... oh yeah, I just finished my one whole day wedding photo shoot this Monday... will share the happiness with you all once it is done ! heee..
Bengster, if I am lucky enough, I will pocket in the nett profit of SGD 250K by 1Q 2009, how I did it, I will write a full details summary of how i do it.. not stocks, but something else, kekekeke...
back to biosensor, it's going to be one dollars, KEKEKEKE
as this counter is concern, since it listed, share holder enjoy zero dividend.
If this is a US partnership, BIO will super cheong!!! Otherwise why halt, must be big news!
Hello to almostthere. Uncle jackjames you MIA to where? I though you have quited on this stock liao. Frankly i was just thinking abt you last nite and suddenly this morning i saw your posting again. Just like Mr Investor also. A bit of voodo feel man.........
Trading Halt means the news must be something substantial enough to affect the share price. Don't tell me its the "mother of all chiong" i mentioned earlier........ the BIG deal??? Should not be so early according to my calculations though. But BIG has the best proven DES technology so deals may be fast and furious. Just have to wait a while and see. I think it should be something positive. Mai Kan Chiong. Just sit back and we may see some opening gap up after lifting of trading halt

mr jackjames shouldn't treat a lonely man like tat. wait he jump, how? let's be tolerant & pity him.
i noticed someone here panic, juz face the fact.
cBrother Bengster, maybe they are going to announce what you have already told us, regard a medical device company accumulating a strategic stake in BIG.
yeah, bengster, I agreed with you! Somebody created a thread himself and self entertaining until he gets bored himself everyday, that's why come to this thread and pollute...
GET LOST !
dun comfort ur self, face the fact. it will drop when trading halt lifted today.
Huahar Ge!!!!!!!!!!!!!1
Happy New Year!!!!!!!!!!!!!
CHEERS!!!!!!!!!!!!!!!!!!!!!!!!!
Trading halt to announce business patnership and cooperation. Great. More and more good news. I agree with almostthere. Don't bother with negative energy.
Happy New Year Bengster68. Cheers to a good year ahead. My suggestion is to ignore. It is negative energy and does not deserve your bother and time. The rest of us are engaged with you positively.
lucky, save by the halt to avoid massive morning sell down today. T+5 today.
Pension Elite |
Posted: 08-Jan-2008 22:23 |
![]() ![]() |
t+5 tommorrow, force selling. |
Paclitaxel drug is toxic in nature and not as effect as limus family drug. Actually Sirolimus is quite a good limus drug. After so many trials comparing both DESs over the last few years, i feel Cypher is a better DES than Taxus. But Taxus is the global market leader and selling about 10% higher than Cypher. Funny isn't it??? Patients are actually paying more for an inferior DES and the inferior DES is selling better than the better one. Doctors must be playing a part in this scam to con patients.
China JWMS uses Sirolimus (a.k.a rapamycin) but on a biodegredable polymer. The problem of JNJ's cypher DES is the durable polymer. JW's EXCEL made-in-china DES has the potential to perform better than Cypher which cost much more.
t+5 tommorrow, force selling.
Sirolimus stents may reduce restenosis in diabetics with coronary disease Source: Reuters Author: Date: Mon, 7 January 2008 Compared with paclitaxel-eluting stents (PES), sirolimus-eluting stents (SES) appear to decrease the risk of in-stent late luminal loss in diabetics with coronary artery disease, new research shows. The optimal drug-eluting stents for diabetic patients has been unclear, lead author Dr. Fabrizio Tomai, from the European Hospital in Rome, and colleagues note in the January issue of Diabetes Care. Comparing PES with SES has been difficult since there are so many individual variables that contribute to neointimal hyperplasia. In the present study, the researchers addressed this problem by comparing PES and SES directly in the same diabetic patient. The study enrolled 60 patients with two or more significant de novo angiographic stenoses in different coronary segments. Overall, 60 lesions were successfully treated with PES and 60 with SES, the report shows. (Another 26 coronary lesions were treated with bare metal stents and were not included in the analysis.) The main outcome measure was the occurrence of angiographic in-stent late luminal loss at eight-month follow-up. This was lower with the SES (0.26 mm) than with the PES (0.50 mm), a significant difference (p = 0.01). On multivariate analysis, the type of drug-eluting stent was the only independent predictor of in-stent late luminal loss. Specifically, in-stent late luminal loss was 2.3-times more likely when a PES rather than a SES was used (p = 0.03). Further research is needed to determine if the better angiographic results achieved with SES actually translate into long-term clinical benefits, the authors conclude.
allright Member |
Posted: 08-Jan-2008 16:12 |
![]() ![]() |
Thanks. That is very technical and I have been reading your postings and noticed you have been very good at this. I think as i am new I will stick to buying and keeping the little i bought though high at .885 |

tommorrow is t+5, trade with care.